EPA:ALERS - Euronext Paris - Matif - FR0013240934 - Common Stock - Currency: EUR
EPA:ALERS (3/7/2025, 7:00:00 PM)
25.35
0 (0%)
The current stock price of ALERS.PA is 25.35 EUR. In the past month the price decreased by -0.59%. In the past year, price increased by 54.01%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France and currently employs 137 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
EUROBIO-SCIENTIFIC
ZA de Courtaboeuf 7 Avenue de Scandinavie, Les Ulis Cedex
Les Ulis ILE-DE-FRANCE FR
Employees: 329
Company Website: https://www.eurobio-scientific.com/
Investor Relations: https://www.eurobio-scientific.com/fr/investisseurs/chiffres-cles
Phone: 331169796480
The current stock price of ALERS.PA is 25.35 EUR.
The exchange symbol of EUROBIO-SCIENTIFIC is ALERS and it is listed on the Euronext Paris - Matif exchange.
ALERS.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALERS.PA and the average price target is 30.6 EUR. This implies a price increase of 20.71% is expected in the next year compared to the current price of 25.35. Check the EUROBIO-SCIENTIFIC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EUROBIO-SCIENTIFIC (ALERS.PA) has a market capitalization of 259.84M EUR. This makes ALERS.PA a Micro Cap stock.
EUROBIO-SCIENTIFIC (ALERS.PA) currently has 329 employees.
EUROBIO-SCIENTIFIC (ALERS.PA) has a support level at 25.3 and a resistance level at 25.36. Check the full technical report for a detailed analysis of ALERS.PA support and resistance levels.
The Revenue of EUROBIO-SCIENTIFIC (ALERS.PA) is expected to grow by 6.07% in the next year. Check the estimates tab for more information on the ALERS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALERS.PA does not pay a dividend.
EUROBIO-SCIENTIFIC (ALERS.PA) will report earnings on 2025-04-08, after the market close.
The PE ratio for EUROBIO-SCIENTIFIC (ALERS.PA) is 39.61. This is based on the reported non-GAAP earnings per share of 0.64 and the current share price of 25.35 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ALERS.PA.
ChartMill assigns a technical rating of 3 / 10 to ALERS.PA. When comparing the yearly performance of all stocks, ALERS.PA is one of the better performing stocks in the market, outperforming 92.49% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA. ALERS.PA gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months ALERS.PA reported a non-GAAP Earnings per Share(EPS) of 0.64. The EPS decreased by -15.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.61% | ||
ROA | 2.12% | ||
ROE | 3.72% | ||
Debt/Equity | 0.44 |
ChartMill assigns a Buy % Consensus number of 84% to ALERS.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -2.22% and a revenue growth 6.07% for ALERS.PA